parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	12 Parkinson's papers of 976	0.66
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 6314

receipt 6321: MT3 in dopamine neurons, braak

power: full sample +0.13 (p 0.597, n 18), 95% CI -0.36 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.18 (p 0.487, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.42 (p 0.084, n 18). could be the mix.
skeptic: leave-one-out range +0.01 to +0.21, sign flips 0; without severely affected donors +0.13 (p 0.597, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MT3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6320: MT3 in astrocytes, braak

power: full sample -0.21 (p 0.398, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.21 (p 0.398, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.21 (p 0.398, n 18). could be the mix.
skeptic: leave-one-out range -0.38 to -0.10, sign flips 0; without severely affected donors -0.21 (p 0.398, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MT3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts